Trial Profile
One Versus Two Versus Three Daily Rapid-Acting Insulin Injections of APIDRA (Insulin Glulisine) as Add-on to Lantus and Oral Sensitizer Basal Therapy in Type 2 Diabetes: a Multicenter, Randomized, Parallel, Open-Label Clinical Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin glulisine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Sanofi
- 09 Jun 2009 Results were reported at the 2009 ADA.
- 06 Jun 2009 Results were presented at the American Diabetes Association annual meeting, according to a sanofi-aventis media release.
- 08 Apr 2009 Trial phase changed from IV to III as reported by ClinicalTrials.gov.